Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting

被引：121

作者：

Rotolo, Antonia ^{[1
]}

Caputo, Valentina S. ^{[1
]}

Holubova, Monika ^{[1
,2
]}

Baxan, Nicoleta ^{[3
]}

Dubois, Olivier ^{[3
]}

Chaudhry, Mohammed Suhail ^{[1
]}

Xiao, Xiaolin ^{[1
]}

Goudevenou, Katerina ^{[1
]}

Pitcher, David S. ^{[1
]}

Petevi, Kyriaki ^{[1
]}

Kachramanoglou, Carolina ^{[4
]}

Iles, Sandra ^{[5
]}

Naresh, Kikkeri ^{[1
]}

Maher, John ^{[6
]}

Karadimitris, Anastasios ^{[1
]}

机构：

[1] Imperial Coll London, Dept Med, Ctr Haematol, London, England

[2] Charles Univ Prague, Med Fac Pilsen, Biomed Ctr, Alej Svobody 76, Plzen 32300, Czech Republic

[3] Imperial Coll London, Dept Med, Biol Imaging Ctr, London, England

[4] Imperial Coll Healthcare NHS Trust, Dept Neuroradiol, London, England

[5] Hammersmith Hosp, Northwest London Pathol, Cellular Pathol, London, England

[6] Kings Coll London, Guys Hosp, Sch Canc & Pharmaceut Sci, London, England

来源：

CANCER CELL | 2018年 / 34卷 / 04期

关键词：

KILLER T-CELLS; INVARIANT NKT CELLS; CHRONIC LYMPHOCYTIC-LEUKEMIA; VERSUS-HOST-DISEASE; B-CELLS; ADOPTIVE IMMUNOTHERAPY; ALPHA-GLYCOSYLCERAMIDE; DISTINCT SUBSETS; GENE-EXPRESSION; RECEPTOR;

D O I：

10.1016/j.ccell.2018.08.017

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Chimeric antigen receptor anti-CD19 (CAR19)-T cell immunotherapy-induced clinical remissions in CD19(+) B cell lymphomas are often short lived. We tested whether CAR19-engineering of the CD1d-restricted invariant natural killer T (iNKT) cells would result in enhanced anti-lymphoma activity. CAR19-iNKT cells co-operatively activated by CD1d- and CAR19-CD19-dependent interactions are more effective than CAR19-T cells against CD1d-expressing lymphomas in vitro and in vivo. The swifter in vivo anti-lymphoma activity of CAR19-iNKT cells and their enhanced ability to eradicate brain lymphomas underpinned an improved tumor-free and overall survival. CD1D transcriptional de-repression by all-trans retinoic acid results in further enhanced cytotoxicity of CAR19-iNKT cells against CD19(+) chronic lymphocytic leukemia cells. Thus, iNKT cells are a highly efficient platform for CAR-based immunotherapy of lymphomas and possibly other CD1d-expressing cancers.

引用

页码：596 / +

页数：26

共 50 条

[31] Dual CAR-T Cells Targeting CD19 and CD37 Are Effective in Target Antigen Loss B-cell Tumor Models
Imai, Kanae
Takeuchi, Yuki
Terakura, Seitaro
Okuno, Shingo
Adachi, Yoshitaka
Osaki, Masahide
Umemura, Koji
Hanajiri, Ryo
Shimada, Kazuyuki
Murata, Makoto
Kiyoi, Hitoshi
MOLECULAR CANCER THERAPEUTICS, 2024, 23 (03) : 381 - 393
[32] Tandem CD19/CD22 Dual Targets CAR-T Cells Therapy Obtains Superior CR Rate Than Single CD19 CAR-T Cells Infusion As Well As Sequential CD19 and CD22 CAR-T Cells Infusion for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Patients
Liu, Sining
Zhang, Xinyue
Dai, Haiping
Cui, Qingya
Cui, Wei
Yin, Jia
Li, Zheng
Xue, Shengli
Yang, Chunxiu
Yang, Xiao
Qiu, Huiying
Miao, Miao
Chen, Suning
Jin, Zhengming
Fu, Chengcheng
Li, Caixia
Sun, Aining
Han, Yue
Wang, Ying
Yu, Lei
Wu, Depei
Tang, Xiaowen
BLOOD, 2021, 138
[33] ARI0003: Co-transduced CD19/BCMA dual-targeting CAR-T cells for the treatment of non-Hodgkin lymphoma
Bachiller, Mireia
Barcelo-Genestar, Nina
Rodriguez-Garcia, Alba
Alserawan, Leticia
Dobano-Lopez, Celia
Gimenez-Alejandre, Marta
Castellsague, Joan
Colell, Salut
Otero-Mateo, Marc
Antonana-Vildosola, Asier
Espanol-Rego, Marta
Ferruz, Noelia
Pascal, Mariona
Martin-Antonio, Beatriz
Anguela, Xavier M.
Fillat, Cristina
Olesti, Eulalia
Calvo, Gonzalo
Juan, Manel
Delgado, Julio
Perez-Galan, Patricia
Urbano-Ispizua, Alvaro
Guedan, Sonia
MOLECULAR THERAPY, 2025, 33 (01) : 317 - 335
[34] CD28-COSTIMULATED CD19 CAR T CELLS FOR PEDIATRIC RELAPSED AND REFRACTORY MATURE B-CELL LYMPHOMA
Jacoby, Elad
Adam, Etai
Abramovich, Alon
Shapira, Adi
Hutt, Daphna
Itzhaki, Orit
Bielorai, Bella
Toren, Amos
BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 563 - 564
[35] Dual targeting of CD19 and CD22 against B-ALL a novel-sensitivity aCD22 CAR
Kokalaki, Evangelia
Ma, Biao
Ferrari, Mathieu
Grothier, Thomas
Hazelton, Warren
Manzoor, Somayya
Costu, Eren
Taylor, Julia
Bulek, Anna
Srivastava, Saket
Gannon, Isaac
Jha, Ram
Gealy, Rosalind
Stanczuk, Lukas
Rizou, Tatiana
Robson, Mathew
El-Kholy, Mohamed
Baldan, Vania
Righi, Matteo
Sillibourne, James
Thomas, Simon
Onuoha, Shimobi
Cordoba, Shaun
Pule, Martin
MOLECULAR THERAPY, 2023, 31 (07) : 2089 - 2104
[36] A Refractory B-ALL Patient Relapsed with Leukemia Cells Expressing CD19 and Anti-CD19 CAR Gene 14 Days after CR from Anti-CD19 CAR T-Cell Therapy
Liu Meijing
Cui, Rui
Mu, Juan
Yuan, Ji-Jun
Mou, Nan
Yang, Zhen-xing
Jiang Yan-yu
Meng Juanxia
Deng, Qi
BLOOD, 2019, 134
[37] Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma
Jackson, Zachary
Roe, Anne
Sharma, Ashish Arunkumar
Lopes, Filipa Blasco Tavares Pereira
Talla, Aarthi
Kleinsorge-Block, Sarah
Zamborsky, Kayla
Schiavone, Jennifer
Manjappa, Shivaprasad
Schauner, Robert
Lee, Grace
Liu, Ruifu
Caimi, Paolo F.
Xiong, Ying
Krueger, Winfried
Worden, Andrew
Kadan, Mike
Schneider, Dina
Orentas, Rimas
Dropulic, Boro
Sekaly, Rafick-Pierre
de Lima, Marcos
Wald, David N.
Reese, Jane S.
FRONTIERS IN IMMUNOLOGY, 2020, 11
[38] Signatures of response to CD19 CAR-T-cells in diffuse large B-cell lymphoma
Ohlmeier, Luisa
Loeber, Jens
Grunert, Corinna
Busse, Antonia
Chapuy, Bjoern
EUROPEAN JOURNAL OF IMMUNOLOGY, 2024, 54 : 793 - 793
[39] Evasion of αCD19 CAR T-Mediated Killing By Rituximab-Chemotherapy Resistant Lymphoma Cells
Mandeville, Taylor K.
Wright, Jacob P.
Mavis, Cory
Cortese, Matthew J.
Rosario, Spencer
Olejniczak, Scott
Hernandez-Ilizaliturri, Francisco
BLOOD, 2024, 144 : 5762 - 5763
[40] DUAL CD19/CD22 CAR T CELLS SHOW FEASIBILITY IN PEDIATRIC/YOUNG ADULT B-ALL
不详
CANCER DISCOVERY, 2021, 11 (12) : 2958 - 2958

← 1 2 3 4 5 →